Organovo Holdings, Inc. — Form 10-Q Summary
Entity note: The supplied filing is for Organovo Holdings, Inc., not Vivosim Labs, Inc. It covers the quarter and nine months ended September 30, 2012; the interim financial statements are unaudited.
Business context and reporting period
Organovo was a development-stage company developing and commercializing technology to produce 3D human tissues for research, drug development, and potential therapeutic applications. It reported no significant revenue from its planned principal operations. On February 8, 2012, it completed a merger accounted for as a reverse merger and recapitalization, followed by private-placement financings.
Financial performance and position
- Revenue: Third-quarter revenue was $469,238, up 102% from $231,974 a year earlier. Nine-month revenue was $848,213, up 40% from $606,138. Revenue was primarily from research collaborations and grants; product revenue was zero in 2012 for both periods.
- Operating results: Third-quarter operating loss was $3.62 million, compared with $622,434 a year earlier. Nine-month operating loss was $6.40 million, versus $1.59 million. Operating expenses were $4.09 million for the quarter and $7.24 million for nine months, including higher research and development spending and public-company costs.
- Net income (loss): The quarter showed net income of $38.48 million, versus a loss of $805,242 in 2011. This was principally due to a $42.25 million noncash gain from the change in fair value of warrant liabilities. For the nine months, the company recorded a net loss of $33.99 million, versus $1.88 million in 2011.
- Margins: Product gross margin is not meaningfully assessable because 2012 product revenue and cost of product revenue were both zero. The filing does not present a useful consolidated operating margin for this development-stage business.
- Cash flow: Nine-month operating cash use was $7.71 million; investing cash use was $344,071; and financing provided $15.39 million. Cash and cash equivalents rose to $7.68 million from $339,607 at December 31, 2011.
- Liquidity: Current assets were $8.23 million and current liabilities $976,225, yielding working capital of $7.25 million. Restricted cash was $88,321. Management said available cash, together with anticipated financing and collaboration and grant receipts, was expected to fund planned operations for at least 12 months.
- Debt and liabilities: No convertible notes were outstanding at September 30, 2012. Capital lease obligations totaled $29,557. Warrant derivative liabilities were $35.47 million, contributing to total liabilities of $36.47 million and stockholders’ deficit of $27.42 million; the company’s reported total assets were $9.04 million.
Material changes versus the prior comparable period
- Quarterly and nine-month revenue increased, driven by collaboration and grant revenue; nine-month product revenue fell from $100,000 in 2011 to zero.
- Operating expenses rose sharply as the company expanded research and administrative staffing and incurred costs associated with becoming a public company. R&D staffing increased from 12 to 22; general and administrative staffing increased from 4 to 9.
- Cash increased substantially following first-quarter private-placement proceeds. The company reported approximately $13.8 million in gross proceeds from common-stock sales during the first nine months of 2012.
- Shares outstanding increased to 46,969,141. There were 22,535,957 outstanding warrants, generally exercisable at $1.00, and additional shares reserved under equity plans, creating substantial potential dilution.
Outlook, risks, contingencies, and unusual items
- Management stated it expected available resources and anticipated receipts to support planned operations for at least 12 months, but also said further capital would be needed for product development and commercialization. Additional financing was not assured and could dilute shareholders or impose restrictive debt terms.
- The large warrant liability is measured using Level 3 assumptions and a Monte Carlo model. The filing cautions that changes in share price, volatility, remaining term, and other inputs can cause significant quarter-to-quarter earnings volatility.
- The company recorded $19.02 million of expense when the fair value of warrants issued in the financing exceeded proceeds, $2.13 million of merger financing costs, and a $158,366 loss on fixed-asset disposal. The third-quarter warrant fair-value gain materially inflated reported net income but did not represent operating cash generation.
- The new office and laboratory lease had base rent of approximately $38,800 per month, with a 48-month term and 3% annual escalators; future minimum operating lease payments totaled $1.62 million.
- Management reported disclosure controls and procedures were effective at period-end and no material change in internal control over financial reporting. The company reported no ongoing legal proceedings and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Confirm the correct issuer: the filing is for Organovo Holdings, Inc., notwithstanding the request metadata naming Vivosim Labs, Inc.
- Review the warrant terms, valuation assumptions, and sensitivity of the $35.47 million derivative liability; distinguish the noncash quarterly gain from operating performance.
- Assess cash runway against the reported $7.71 million nine-month operating cash use, planned development spending, and the company’s stated need for additional capital.
- Evaluate dilution from outstanding warrants, options, and equity-plan reserves, as well as the terms and timing of any future financing.
- Track collaboration and grant revenue, which supported reported revenue while product revenue remained zero.